Skip to main content
Advertisement
Advertisement
IAM
IAM logo
Iambic Therapeutics, Inc. Common Stock
13.11
USD
Sponsored
-1.15
-8.06%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

13.79

+0.69
+5.23%

Iambic Therapeutics, Inc. Common Stock (IAM) Earnings

IAM Earnings Reports

Positive Surprise Ratio

IAM beat 0 of 1 last estimates.

0%

Next Report

Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q3 26 (Revenue/ EPS)
--
/
--
Implied change from Q-- -- (Revenue/ EPS)
--
/
--

Iambic Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 16, 2026, IAM reported earnings of -6.22 USD per share (EPS) for Q3 26, missing the estimate of 0.16 USD, resulting in a -3951.49% surprise. Revenue reached 11.35 million, compared to an expected 36.17 million, with a -68.62% difference. The market reacted with a -9.54% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Iambic Therapeutics, Inc. Common Stock reported EPS of -$6.22, missing estimates by -3951.49%, and revenue of $11.35M, -68.62% below expectations.
The stock price moved down -9.54%, changed from $13.10 before the earnings release to $11.85 the day after.
The next earning report is scheduled for --.
Based on -- analysts, Iambic Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement